A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of XAF5 Gel for Reduction of Submental Fat.
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2016
At a glance
- Drugs XAF 5 (Primary)
- Indications Adipose tissue disorders
- Focus Therapeutic Use
- Sponsors Topokine Therapeutics
- 26 Feb 2016 According to ClinicalTrials.gov record, the primary endpoint has been amended and hence the trial focus has changed from TU to AR
- 26 Feb 2016 Status changed from recruiting to suspended, according to ClinicalTrials.gov record.
- 19 Nov 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2016, according to ClinicalTrials.gov record.